Hans ErikssonChief Medical Officer
Hans is Chief Medical Officer of COMPASS Pathways, leading the clinical development programme.
Hans gained his MD and did his residency in psychiatry at Lund University in Sweden. He also holds a PhD in Cell and Molecular Biology from Lund University, and an executive MBA from Stockholm School of Economics. After having worked as consultant psychiatrist and assisting head of the Psychiatric Centre at Lund University Hospital, he moved to the pharmaceutical industry in 2000. He has been working in different roles with H. Lundbeck and AstraZeneca, especially on the development programmes for escitalopram, quetiapine XR, mecamylamine, and brexpiprazole for major depressive disorder, and for additional psychiatric indications. He had an active role in the successful regulatory submissions of Cipralex, Seroquel XR and Rexulti. He was the global medical lead for Seroquel XR at AstraZeneca, and in his most recent role he was Senior Director and head of clinical development for depression and paediatrics at H. Lundbeck. At COMPASS Pathways, Hans uses his clinical expertise and clinical development experience to lead the development programme.
It is a truly meaningful effort to participate in the development of a novel treatment paradigm for people suffering from severe mental disorders.